Native-like SARS-CoV-2 spike glycoprotein expressed by ChAdOx1 nCoV-19/AZD1222 vaccine

Mostrar otras versiones (1)

Vaccine development against the SARS-CoV-2 virus focuses on the principal target of the neutralizing immune response, the spike (S) glycoprotein. Adenovirus-vectored vaccines offer an effective platform for the delivery of viral antigen, but it is important for the generation of neutralizing antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Yasunori, Mendonça, Luiza, Allen, Elizabeth R., Howe, Andrew, Lee, Mercede, Allen, Joel D., Chawla, Himanshi, Pulido, David, Donnellan, Francesca, Davies, Hannah, Ulaszewska, Marta, Belij-Rammerstorfer, Sandra, Morris, Susan, Krebs, Anna-Sophia, Dejnirattisai, Wanwisa, Mongkolsapaya, Juthathip, Supasa, Piyada, Screaton, Gavin R., Green, Catherine M., Lambe, Teresa, Zhang, Peijun, Gilbert, Sarah C., Crispin, Max
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836103/
https://www.ncbi.nlm.nih.gov/pubmed/33501433
http://dx.doi.org/10.1101/2021.01.15.426463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7836103/
https://www.ncbi.nlm.nih.gov/pubmed/33501433
http://dx.doi.org/10.1101/2021.01.15.426463

Ejemplares similares